🇺🇸 FDA
Patent

US 8741912

Deazapurines useful as inhibitors of Janus kinases

granted A61PA61P11/06A61P17/06

Quick answer

US patent 8741912 (Deazapurines useful as inhibitors of Janus kinases) held by Vertex Pharmaceuticals Incorporated expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61P, A61P11/06, A61P17/06, A61P17/14, A61P19/02